Connie Baum Newman, MD, FACP, FAHA, FAMWA

NewmanConnie B. Newman, MD is an endocrinologist and Adjunct Professor of Medicine at New York University School of Medicine and Academic Visitor at the University of Oxford, UK. She is the 2018-2019 President of the American Medical Women’s Association. Dr. Newman, a physician-scientist with experience in the fields of drug safety and hypercholesterolemia and its relationship to atherosclerotic cardiovascular disease, has designed, conducted and analyzed large long term cardiovascular outcome trials of statins and is a member of the Cholesterol Treatment Trialists’ Collaboration. She co-authored the meta-analysis on cancer events and cancer mortality in 170,000 patients in 27 statin RCTS. She was a member of the Steering Committee of the Collaborative Atorvastatin Diabetes Study (CARDS) which showed that atorvastatin prevents coronary heart disease and stroke in people with type 2 diabetes.

Dr. Newman has written numerous papers on statin safety and statin intolerance, and chairs the Writing Group for the American Heart Association’s Scientific Statement on the safety of statins. She also chairs the Writing Committee for the Endocrine Society clinical practice guideline on the management of dyslipidemia in people with endocrine disorders. Dr. Newman is an FDA appointed consultant to the Endocrine and Metabolic Drugs Advisory Committee.

She is committed to education about lipids, cardiovascular disease, and obesity. She recently chaired the Special Programs Committee of the Endocrine Society which develops and implements CME programs and activities at ENDO and throughout the year. Dr. Newman is a graduate of Weill Cornell Medical College (1978) and Wellesley College (1974).